linifanib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702998
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Linifanib is a type I tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by linifanib (Hernandez-Davies et al, 2011; Nguyen et al, 2017).

Literature References
PubMed ID Title Journal Year
28077790 FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Levis, M, Nguyen, B, Williams, AB, Small, D, Brown, P, Li, L, Young, DJ, Ma, H

Oncotarget 2017
21471285 The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway

Hernandez-Davies, JE, Sakamoto, KM, Heinrich, MC, Tan, X, Glaser, KB, Landaw, EM, Presnell, A, Zape, JP, Griffith, D

Mol. Cancer Ther. 2011
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!